Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Accured Expenses: 2016-2024

Historic Change in Accured Expenses for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to $4.8 million.

  • Solid Biosciences' Change in Accured Expenses rose 198.72% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.8 million, marking a year-over-year increase of 168.41%. This contributed to the annual value of $4.8 million for FY2024, which is 168.41% up from last year.
  • As of FY2024, Solid Biosciences' Change in Accured Expenses stood at $4.8 million, which was up 168.41% from -$7.0 million recorded in FY2023.
  • Over the past 5 years, Solid Biosciences' Change in Accured Expenses peaked at $5.8 million during FY2022, and registered a low of -$7.0 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $1.2 million, with a median of $4.8 million in 2024.
  • In the last 5 years, Solid Biosciences' Change in Accured Expenses skyrocketed by 358.63% in 2022 and then tumbled by 219.46% in 2023.
  • Yearly analysis of 5 years shows Solid Biosciences' Change in Accured Expenses stood at -$1.2 million in 2020, then tumbled by 94.90% to -$2.3 million in 2021, then soared by 358.63% to $5.8 million in 2022, then plummeted by 219.46% to -$7.0 million in 2023, then surged by 168.41% to $4.8 million in 2024.